Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Bader, Peter, Rossig, Claudia, Hutter, Martin, Ayuk, Francis A., Baldus, Claudia D., Buecklein, Veit L., Bonig, Halvard, Cario, Gunnar, Einsele, Hermann, Holtick, Udo, Koenecke, Christian, Kuenkele, Annette, Meisel, Roland, Mueller, Fabian, Mueller, Ingo, Penack, Olaf, Rettinger, Eva, Sauer, Martin G., Schlegel, Paul-Gerhardt, Soerensen, Jan, von Stackelberg, Arend, Feuchtinger, Tobias and Jarisch, Andrea (2022). CD19-CAR-T Cells Are Effective and Safe Treatment of Post-Transplant Relapse in Pediatric and Young Adult Patients with B-Lineage ALL: Real-World Data from Germany. Blood, 140. S. 10407 - 10410. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Buecklein, Veit L., Perez-Perez, Ariel, Rejeski, Kai, Iacoboni, Gloria, Jurinovic, Vindi, Holtick, Udo, Penack, Olaf, Kharboutli, Soraya, Blumenberg, Viktoria, Ackermann, Josephine, Froelich, Lisa, Johnson, Grace, Patel, Kedar, Arciola, Brian, Schmidt, Christian, Albanyan, Omar, Goedel, Philipp, Hoster, Eva, Bullinger, Lars, Mackensen, Andreas, Locke, Frederick L., von Bergwelt, Michael, Barba, Pere, Jain, Michael D. and Subklewe, Marion (2022). Inferior Outcomes of EU Vs. US Patients with Relapsed/Refractory Large B-Cell Lymphoma after CD19 CAR T-Cell Therapy Are Associated with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization and CAR-T Product Selection. Blood, 140. S. 2411 - 2414. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

Goekbuget, Nicola, Fiedler, Walter, Alakel, Nael, Topp, Max S., Hanoun, Maher, Steffen, Bjoern, Waesch, Ralph, Viardot, Andreas, Nachtkamp, Kathrin, Stelljes, Matthias, Poeck, Hendrik, Vucinic, Vladan, Boell, Boris, Beck, Joachim, Fransecky, Lars, Wendelin, Knut, Schneller, Folker, Faul, Christoph, Buecklein, Veit L., Reiser, Lena, Brueggemann, Monika, Serve, Hubert and Schwartz, Stefan (2022). Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL/T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL. Blood, 140. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020

This list was generated on Mon May 6 13:26:12 2024 CEST.